CBD is not considered safe while breastfeeding. No major medical organization endorses its use during lactation, and the limited research available shows that CBD does transfer into breast milk at concentrations higher than those found in the mother’s blood. Without clinical data on how this exposure affects infants, the FDA, the American Academy of Pediatrics, and other health authorities all recommend avoiding CBD products while nursing.
CBD Concentrates in Breast Milk
One of the clearest findings from human research is that CBD doesn’t just pass into breast milk; it accumulates there. A study from Oregon Health & Science University measured cannabinoid levels in both plasma and breast milk of breastfeeding mothers. The median CBD concentration in breast milk was 1.2 ng/ml, compared to 0.6 ng/ml in plasma. The milk-to-plasma ratio for CBD was 2.6, meaning breast milk contained roughly two and a half times the concentration circulating in the mother’s bloodstream.
This accumulation happens because CBD is highly fat-soluble, and breast milk is rich in fat. The compound essentially dissolves into milk fat and stays there. A nursing infant consuming multiple feedings per day would receive repeated low-level doses with no ability to control or measure the amount.
What the Research Still Doesn’t Know
The biggest problem isn’t that CBD has been proven harmful to nursing infants. It’s that almost no one has studied it directly. One of the largest datasets available, a biorepository of 200 breast milk samples from 181 mothers, measured CBD concentrations in milk but did not track what happened to the infants who consumed it. Researchers have explicitly called for studies collecting plasma samples from breastfed infants and tracking neurodevelopmental outcomes, but those studies don’t exist yet.
This gap matters because infants process substances very differently than adults. A newborn’s liver enzymes are immature and develop gradually over the first months of life. Compounds that an adult body clears efficiently may linger much longer in an infant’s system, potentially reaching higher effective concentrations. Without specific pharmacokinetic data in infants, there’s no way to predict how much CBD actually accumulates in a baby’s body over days or weeks of breastfeeding exposure.
What Health Authorities Recommend
The FDA’s position is straightforward: based on existing knowledge, some amount of CBD will be transferred to babies through breast milk, and mothers should avoid cannabis-derived products, including CBD, while breastfeeding. The agency also notes that THC can remain in breast milk for up to six days after use, which is relevant because many CBD products contain trace amounts of THC.
The American Academy of Pediatrics takes a similar stance. Its guidance states that data are insufficient to assess the effects of cannabinoid exposure on infants through breastfeeding, and that maternal marijuana use while breastfeeding is “discouraged.” The AAP specifically notes that cannabis compounds in human milk are “of concern, particularly regarding the infant’s long-term neurobehavioral development.” While this guidance was written primarily about marijuana, it applies to CBD products as well, especially given the contamination issues discussed below.
Contamination in CBD Products
Even if CBD itself were proven harmless to infants, the products carrying it introduce their own risks. A large analysis of 121 commercially available CBD edibles found lead in 42% of products, mercury in 37%, and arsenic in 28%. Four products exceeded California’s safety threshold for daily lead consumption in just two servings. Phthalates, a class of industrial chemicals linked to hormonal disruption, were detected in 13% to 80% of products depending on the specific compound tested.
These contaminants were not related to CBD potency, meaning you can’t predict contamination levels based on the product’s labeled strength. Because CBD products are not regulated as pharmaceuticals in the United States, there is no mandatory testing standard that guarantees a product is free of heavy metals, pesticides, or undisclosed THC. For a nursing infant with a developing brain and minimal body weight, even trace contaminant exposure carries outsized risk.
The THC Problem in CBD Products
Many people choose CBD specifically because it doesn’t produce a high, but “CBD-only” products frequently contain small amounts of THC. Full-spectrum CBD products are legally permitted to contain up to 0.3% THC, and independent testing has found some products exceed their labeled amounts. THC is the cannabinoid with the most documented concern during breastfeeding. The FDA warns it may affect a newborn’s brain development, potentially contributing to hyperactivity, poor cognitive function, and other long-term consequences. THC also concentrates in breast milk, with a milk-to-plasma ratio even higher than CBD’s (median of 7.0 in the Oregon Health & Science University study).
If you’re using a CBD product that contains even small amounts of THC, your infant could be exposed to both compounds simultaneously through breast milk, compounding the unknowns.
Alternatives for Postpartum Symptoms
Many people turn to CBD while breastfeeding because they’re looking for relief from postpartum anxiety, pain, sleep disruption, or low mood. These are real and common problems, and finding safe options matters.
For postpartum depression and anxiety, the CDC recommends that healthcare providers discuss both medication and non-medication options with breastfeeding mothers. Several antidepressants have well-studied safety profiles during lactation, with decades of data on infant exposure levels and outcomes. Individual or group therapy, particularly cognitive behavioral therapy, also has strong evidence for postpartum mood disorders and involves zero chemical exposure for the infant.
For pain management, options like acetaminophen and ibuprofen transfer into breast milk at very low levels and have long safety track records during breastfeeding. Physical therapy, heat or cold therapy, and gradual return to movement can address musculoskeletal pain without systemic medication. The key difference between these options and CBD is data: doctors know how much of these substances reaches the infant and what the effects are, while CBD remains largely unmeasured in this context.